MEDACTA GROUP N
MEDACTA GROUP N
- CHF (-)
- 15 min delayed data - Switzerland SWX Stocks
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: MOVE
ISIN: CH0468525222

Medacta Announces First U.S. Surgery with MectaScrew PEEK following FDA Clearance

  • 46


EQS Group-Media / 04.11.2019 / 19:00

Media Release
Medacta Announces First U.S. Surgery with MectaScrew PEEK following FDA Clearance

CASTEL SAN PIETRO, 4 November 2019 - Medacta is proud to announce the successful completion of the first U.S. surgery utilizing its MectaScrew PEEK Interference Screw for ligament refixation.

The MectaScrew PEEK, which received clearance from the U.S. Food and Drug Administration (FDA) in June, is one of Medacta's most recent sports medicine offerings. As part of the Medacta Single Bundle ACL set, it is intended for knee arthroscopy and indicated for reconstructive treatment of ruptured anterior and posterior cruciate ligaments for hamstring and bone-tendon-bone repairs.

The MectaScrew PEEK features several noteworthy design features, including a blunt thread, which protects the graft from laceration, while ensuring fixation strength, as well as sharp threads at the driver tip that gradually increase in width as the screw goes from distal to proximal to facilitate screw insertion. The associated driver also features a tip design that enables strong retention of the screw once positioned on the tip of the instrument.

The first single bundle ACL surgery in the United States was completed by Akbar Nawab, M.D., at Ellis and Badenhausen Orthopaedics (Louisville, Kentucky) on September 24. "The implant and associated instrumentation performed very well," said Dr. Nawab. "The screw started nicely and provided secure fixation without any damage to the graft, while the instrumentation's ergonomic design made each instrument easy and natural to use. I feel very confident starting my patient in an accelerated rehabilitation program."

This surgery follows the first single bundle ACL performed in Australia in August 2019 and is the start of Medacta's sports medicine presence in the United States.

Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
[email protected]

About Medacta
Medacta is an international company specializing in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS") technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated "MySolutions" technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.



Issuer: Medacta Group SA
Key word(s): Advertisement/Communication

End of Corporate News


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: [email protected], [email protected]
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 903815

 
End of News EQS Group Media

903815  04.11.2019 

fncls.ssp?fn=show_t_gif&application_id=903815&application_name=news&site_id=centralchart
EQS Group
EQS Group

EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.